Mid-Afternoon Market Update: Nasdaq Rises 50 Points; Jefferies Shares Drop
Toward the end of trading Wednesday, the Dow traded up 0.05% to 36,269.24 while the NASDAQ rose 0.35% to 15,205.90. The S&P also rose, gaining, 0.26% to 4,725.52.
Mid-Day Market Update: Crude Oil Rises 2%; Philips Shares Plummet
Midway through trading Wednesday, the Dow traded up 0.26% to 36,346.85 while the NASDAQ rose 0.77% to 15,270.07. The S&P also rose, gaining, 0.57% to 4,739.98.
Aclaris Therapeutics Offers R&D Update
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today provides an update on the status of certain of its
Looking Into Aclaris Therapeutics’s Return On Capital Employed
Benzinga Pro data, Aclaris Therapeutics (NASDAQ:ACRS) reported Q3 sales of $1.66 million. Earnings fell to a loss of $20.30 million, resulting in a 12.71% decrease from last quarter.
Aclaris Therapeutics Q3 EPS $(0.35) Down From $(0.25) YoY, Sales $1.66M Up From $1.45M YoY
Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.35) per share. This is a 40 percent decrease over losses of $(0.25) per share from the same period last year. The company reported $1.66 million in
The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 2)
Looking into Aclaris Therapeutics’s Return on Capital Employed
After pulling data from Benzinga Pro it seems like during Q2, Aclaris Therapeutics's (NASDAQ:ACRS) reported sales totaled $1.82 million. Despite a 36.89% in earnings, the company posted a loss of $18.01 million.
Aclaris Therapeutics Announces Proposed Settlement And Settlement Hearing Of Stockholder Derivative Action
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that a settlement hearing (the